Hepatocellular Carcinoma News and Research

RSS

Hepatocellular Carcinoma is a type of adenocarcinoma, the most common type of liver tumor.

Drug sensitivity of hepatocellular cancer cells may provide new insights on tumor biology

Oncotarget published "Effect of cell microenvironment on the drug sensitivity of hepatocellular cancer cells" which reported that this study aimed to investigate whether Hepatocellular Cancer (HCC) cells cultured in more native conditions have an altered phenotype and drug sensitivity compared to those cultured in standard conditions.

8 Jun 2021

Nanopore sequencing contradicts human genome integration of SARS-CoV-2

Now a new preprint research paper posted to the bioRxiv* server dismisses the possibility, raised by that study, that the virus inserts its genetic material into the host cell’s genome.

2 Jun 2021

Molecular subtype of cancer preferentially affects people with Indigenous ancestry

Oncotarget published "Global DNA hypermethylation pattern and unique gene expression signature in liver cancer from patients with Indigenous American ancestry" which reported that contrasting with this pattern, the age structure of HCC in Andean people displays a bimodal distribution with half of the patients developing HCC in adolescence and early adulthood.

2 Jun 2021

UCL scientists identify new immunotherapy to combat hepatitis B virus

Scientists at UCL have identified a new immunotherapy to combat the hepatitis B virus (HBV), the most common cause of liver cancer in the world.

14 May 2021

New class of anti-cancer compounds effectively kills liver and breast cancer cells

A team of Oregon State University scientists has discovered a new class of anti-cancer compounds that effectively kill liver and breast cancer cells.

12 May 2021

New study launched to more accurately diagnose early hepatocellular carcinoma

A first of its kind cohort study on patients at high risk of developing primary liver cancer also known as hepatocellular carcinoma (HCC), has been launched to diagnose HCC more accurately at an earlier stage and to predict an individual's likelihood of developing the cancer.

3 May 2021

A collaborative effort to evaluate treatment of liver and pancreatic tumors

The University of Texas MD Anderson Cancer Center and TriSalus Life Sciences today announced a strategic research collaboration to evaluate the treatment of tumors of the pancreas and liver by integrating interventional delivery of SD-101.

8 Apr 2021

Researchers discover a gene family strongly implicated in the development of liver cancer

In a comprehensive analysis of human gene activation data, researchers from the Centenary Institute have discovered that the dipeptidyl peptidase-4 (DPP4) gene family is strongly implicated in the development of human hepatocellular carcinoma (HCC), the most common type of primary liver cancer.

7 Apr 2021

Bariatric surgery can reduce the risk of obesity-related cancers, study shows

Bariatric surgery can significantly reduce the risk of cancer--and especially obesity-related cancers--by as much as half in certain individuals, according to a study by researchers at Rutgers Robert Wood Johnson Medical School's Center for Liver Diseases and Liver Masses.

26 Mar 2021

Study examines m6A regulators and m6A-related genes through integrated bioinformatic analysis

Announcing a new article publication for BIO Integration journal. In this article the authors Jingdun Xie, Zhenhua Qi, Xiaolin Luo, Fang Yan, Wei Xing, Weian Zeng, Dongtai Chen and Qiang Li; from Sun Yat-sen University, Guangzhou, Guangdong, China discuss integration analysis of m6A regulators and m6A-related genes in hepatocellular carcinoma (HCC).

10 Mar 2021

Study shows how m6A regulators influence metabolic heterogeneity of hepatocellular carcinoma

Cancer cells acquire growth advantages over normal cells in myriad ways. Changes in cell programming allow these cells to grow in an uncontrolled fashion, thereby forming the cancer mass.

23 Feb 2021

Ionic liquid formulation kills cancer cells, allows uniform distribution of chemotherapy to tumors

A Mayo Clinic team, led by Rahmi Oklu, M.D., Ph.D., a vascular and interventional radiologist at Mayo Clinic, in collaboration with Samir Mitragotri, Ph.D., of Harvard University, report the development of a new ionic liquid formulation that killed cancer cells and allowed uniform distribution of a chemotherapy drug into liver tumors and other solid tumors in the lab.

11 Feb 2021

Gut microbiome can modulate the immune response in liver cancer patients with NAFLD

The distinctive gut microbiome profile of a person with liver cancer linked to non-alcoholic fatty liver disease (NAFLD) could be the key to predicting someone's risk of developing the cancer, say researchers from the UNSW Microbiome Research Centre.

4 Feb 2021

Reduced expression of TBX15 in tumor tissue represents a prognostic biomarker for HCC patients

The cover for issue 52 of Oncotarget features Figure 1, "Volcano plots of DNA methylation in tumor tissues compared with nontumor tissue," published in "Reduction of T-Box 15 gene expression in tumor tissue is a prognostic biomarker for patients with hepatocellular carcinoma" by Morine, et al. which reported that the authors conducted a genome-wide analysis of DNA methylation of the tumor and non-tumor tissue of 15 patients with Hepatocellular carcinoma (HCC), and revealed TBX15 was the most hypermethylated gene of the tumor.

25 Jan 2021

Researchers design armored immune cells to attack recurring cancer in liver transplant patients

Duke-NUS Medical School researchers, together with collaborators in Singapore, have designed armored immune cells that can attack recurring cancer in liver transplant patients, while temporarily evading immunosuppressant drugs patients take to avoid organ rejection.

19 Jan 2021

Liver cancer cells cause stromal cells to secrete protein that enhances tumor growth

Hepatocellular carcinoma (HCC), frequently seen in patients with liver cirrhosis caused by alcohol abuse or chronic viral hepatitis, is the most common form of liver cancer worldwide.

6 Jan 2021

Eureka's InvisiMask human antibody nasal spray offers protection against SARS-CoV-2 in mice

Eureka Therapeutics, Inc. announced today successful preclinical results from its InvisiMask™ Human Antibody Nasal Spray in mice, which offers protection against SARS-CoV-2 S pseudotyped virus infection for up to 10 hours.

14 Dec 2020

Combination therapy found to be effective against treatment-resistant hepatocellular carcinoma

A combination cancer therapy that is effective against treatment-resistant hepatocellular carcinoma (HCC) by inhibiting tumor growth and increasing survival has been identified by researchers at Massachusetts General Hospital.

30 Nov 2020

SARS-CoV-2 viral antigens found in non-pulmonary tissues in recovering patients

A team of researchers in Singapore, led by Dr. Joe Yeong, and Prof. Tony Kiat Hon Lim, have reported the presence of residual SARS-CoV-2 ribonucleic acid (RNA) – the virus' genetic material – in stool samples and gastrointestinal tissues from patients recovering from the coronavirus disease 2019 (COVID-19).

8 Nov 2020

Dietary supplement helps prevent fatty liver disease in rats

A recent study by researchers at the University of Jyväskylä was successful in partially preventing fatty liver disease in rats.

4 Nov 2020